The dermatology textbooks I learned from positioned hydroquinone 4% as the first-line topical treatment for post-inflammatory hyperpigmentation in skin of color. That position made sense at the time. Hydroquinone had the strongest efficacy evidence base, the longest clinical track record, and the most predictable response curve in published trials.
The position is no longer correct.
Three factors have shifted the calculus. First, regulatory access to hydroquinone has narrowed substantially — the 2020 CARES Act eliminated OTC hydroquinone in the US, and EU restrictions have tightened over the same period. Second, the side effect profile in long-term use (ochronosis, paradoxical hyperpigmentation, contact dermatitis) has been better characterized, and the risks are disproportionately concentrated in SoC patients who use it for extended courses. Third, the alternatives have accumulated enough SoC-specific evidence to support them as primary options rather than substitutes.
The three alternatives — topical dapsone, azelaic acid, and tranexamic acid — each address a different subset of PIH presentations better than hydroquinone does. The ranking depends on whether the PIH is acne-driven, melasma-overlap, or post-procedure. I’ll walk through what each does, where it fits, and how to sequence them.
Why hydroquinone is no longer first-line in 2026
Hydroquinone competitively inhibits tyrosinase. The mechanism is potent and well-characterized. The problem is what happens with sustained exposure in Fitzpatrick IV-VI skin.
Ochronosis — paradoxical bluish-black hyperpigmentation from cumulative hydroquinone exposure — affects approximately 1-5% of long-term SoC users at therapeutic concentrations. The risk increases with duration of use, prior hydroquinone courses, and concentrations above 4%. Once established, ochronosis is difficult to reverse and represents a treatment failure that’s worse than the original pigmentation problem.
Contact dermatitis from hydroquinone occurs at meaningful rates — roughly 5-10% of treated patients — and the inflammatory response in SoC skin triggers the same PAR-2 mediated PIH pathway that drove the original pigmentation. The patient experiences treatment-induced worsening.
Regulatory access constrains compliance. In the US, hydroquinone now requires a prescription, which adds cost, clinic visits, and access friction. In the EU, OTC hydroquinone has been restricted since 2001. Patients who could previously self-manage with OTC hydroquinone now need clinical involvement.
The three alternatives address these failure modes without sacrificing the therapeutic efficacy that made hydroquinone first-line in the first place.
Azelaic acid — the universally-tolerable option
Azelaic acid is a dicarboxylic acid naturally produced by the yeast Malassezia furfur. Topically, it has three mechanisms relevant to PIH and acne: selective tyrosinase inhibition (acts preferentially on hyperactive melanocytes rather than baseline melanocytes), anti-inflammatory effects, and antibacterial activity against C. acnes.
The selective tyrosinase inhibition is the most clinically important feature. Unlike hydroquinone, which lightens all skin it touches, azelaic acid acts predominantly on hyperactive melanocytes. The clinical translation: it lightens hyperpigmentation without lightening surrounding normal skin, which means you can’t develop the patchy halo effect that hydroquinone monotherapy produces in some SoC patients.
Pickering and Mahon’s 1986 work (Cutis) characterized the mechanism. The clinical evidence at 15-20% topical concentrations has accumulated over four decades and includes specific evidence in SoC populations for both melasma and PIH.
The trade-offs: azelaic acid is slower than hydroquinone. Expect 12-20 weeks for meaningful pigment improvement, vs. 8-12 weeks on hydroquinone. The slower timeline is offset by the lower side effect risk and the ability to maintain treatment indefinitely without ochronosis concerns.
Commercial formulations: prescription azelaic acid 15% (Finacea, Azelex) and OTC azelaic acid 10-20% (The Ordinary 10%, Paula’s Choice 10%, Naturium 10%). The OTC products are reasonable starting points; prescription 15-20% delivers faster results when access is available.
For most acne-PIH presentations in SoC, azelaic acid is now the right first-line choice.
Topical dapsone — for inflammatory acne with active PIH
Dapsone is a sulfone antibiotic with anti-inflammatory effects mediated through neutrophil function suppression. Topical formulations (5% and 7.5% gel) were developed for inflammatory acne and have accumulated specific evidence in SoC populations over the past fifteen years.
The mechanism is relevant for the patient subgroup with active inflammatory acne and persistent PIH. Topical dapsone reduces the inflammatory acne directly (the cause of the PIH) while having a lower irritation profile than benzoyl peroxide. The reduced irritation translates to less new PIH while the old PIH fades.
Stein Gold and colleagues’ 2017 work (J Drugs Dermatol) documented the SoC-specific outcomes. The PIH outcomes in their dapsone arm meaningfully outperformed BP control in Fitzpatrick IV-VI cohorts, with comparable acne control.
The trade-offs: dapsone is prescription-only and requires baseline G6PD screening (G6PD deficiency contraindicates oral dapsone but topical use is generally safe; some clinicians still screen). Cost is meaningfully higher than OTC alternatives.
For inflammatory acne with persistent PIH in SoC patients where BP has failed or caused PIH escalation, topical dapsone is the right pivot. It’s not a first-line for PIH without active acne — the mechanism specifically addresses the inflammatory driver.
Tranexamic acid — for melasma-overlap PIH
Tranexamic acid (TXA) suppresses plasmin-mediated melanocyte activation. The mechanism is most relevant in melasma, where plasmin signaling is upregulated, but the same pathway contributes to refractory PIH that has a vascular component.
Topical TXA at 2-5% concentrations has accumulated strong evidence for SoC melasma since Cestari and colleagues’ 2014 review (J Drugs Dermatol). The clinical translation: TXA is the right choice when the PIH presentation has overlapping melasma features (symmetric distribution, hormonal triggers, sun-correlated worsening) or when standard PIH protocols have failed at 12-16 weeks.
Oral TXA at 250-500mg twice daily is increasingly prescribed for refractory melasma. Contraindications include thrombotic risk factors, hormonal contraception interactions, and pregnancy — it requires medical supervision and shouldn’t be self-administered.
For PIH that hasn’t responded to azelaic acid in 12-16 weeks and shows any melasma overlap features, topical TXA 3% is the next escalation.
The decision matrix
| PIH presentation | First-line | Why |
|---|---|---|
| Acne PIH, mild-moderate, no active acne | Azelaic acid 15-20% | Selective tyrosinase inhibition, durable safety |
| Acne PIH, active inflammatory acne | Topical dapsone 5-7.5% | Treats cause + lower irritation than BP |
| Comedonal acne with PIH | Adapalene 0.1% + azelaic acid 10% | Comedolytic + PIH fade in parallel |
| Post-procedure PIH | Azelaic acid 15% + niacinamide 4% | Predictable response, low irritation |
| Melasma-overlap PIH | Topical TXA 3% + azelaic acid 10% | Plasmin suppression + tyrosinase inhibition |
| Refractory PIH (12+ weeks failure) | Topical TXA 3% + oral TXA (if appropriate) | Different mechanism than primary failure |
| Hori’s-overlap PIH (dermal component) | Q-switched Nd:YAG referral | Topical actives don’t reach dermal pigment |
Stacking sequences that work
The clinical principle: pick one primary active matched to the dominant PIH driver, layer supporting therapy that doesn’t compete for the same receptors.
Active inflammatory acne with PIH: dapsone 7.5% PM (acne + light PIH effect), niacinamide 4% AM (melanosome transfer inhibition), mineral SPF.
Post-acne PIH, acne controlled: azelaic acid 15% PM (primary), niacinamide 4% AM (supportive), kojic acid 1% AM 2-3x weekly (additional tyrosinase support if azelaic alone is underpowered).
Melasma-overlap PIH: topical TXA 3% bid (primary), azelaic acid 10% PM (complementary mechanism), niacinamide 4% AM, mineral SPF with iron oxide (visible light coverage).
Refractory after 16 weeks of azelaic acid: discontinue, switch to topical TXA 3% bid + alpha-arbutin 2% PM, photograph at week 0 of the new protocol, reassess at week 12.
The mistake I see most often is rotating actives every 4-6 weeks before any of them has had time to produce a measurable effect. PIH treatment timelines are months, not weeks. Pick a protocol, photograph the baseline, hold the protocol for 12-16 weeks before deciding it has failed.
When you still need a derm referral
Three scenarios where self-management with these actives isn’t the right path:
PIH that hasn’t responded to a 16-week trial of an appropriately-matched protocol. This usually indicates either a wrong diagnosis (often melasma being treated as PIH, or dermal pigment that won’t respond to topicals) or refractory pigmentation that needs prescription escalation.
Concomitant active dermatologic conditions complicating the PIH (rosacea, perioral dermatitis, contact dermatitis from other products). The complication needs to be addressed before the pigmentation work can succeed.
PIH that’s developing or worsening despite an appropriate protocol. This is a red flag for ongoing inflammatory drivers that need clinical workup — autoimmune processes, drug reactions, persistent contact triggers.
For these cases, the OTC active selection isn’t the constraint. The diagnostic clarity is.
FAQ
*Is azelaic acid better than hydroquinone for darker skin?*
For most PIH presentations in 2026, yes. Azelaic acid’s selective tyrosinase inhibition lightens hyperactive melanocytes without lightening surrounding skin, eliminating the patchy halo risk hydroquinone monotherapy carries. The trade-off is slower onset — 12-20 weeks vs. 8-12 weeks for hydroquinone — offset by the ability to use it indefinitely without ochronosis risk.
*What’s topical dapsone and why is it used for acne PIH?*
Topical dapsone is a sulfone antibiotic with anti-inflammatory effects through neutrophil suppression. The mechanism addresses inflammatory acne with a lower irritation profile than benzoyl peroxide, which translates to less new PIH while existing PIH fades. It’s prescription-only and requires either G6PD screening or topical-only use to manage the deficiency-related contraindications.
*Can I take oral tranexamic acid for melasma?*
Oral tranexamic acid at 250-500mg twice daily has strong evidence for refractory melasma and is increasingly prescribed in dermatology practice. Contraindications include thrombotic risk factors, hormonal contraception interactions, and pregnancy. It requires medical supervision and shouldn’t be self-administered.
*What’s the safest first-line PIH treatment for Fitzpatrick V skin?*
Azelaic acid 15-20% has the strongest combination of efficacy, safety, and durability for Fitzpatrick V-VI skin in 2026. It’s appropriate for indefinite use without the long-term risks associated with hydroquinone, and its selective mechanism avoids the patchy lightening that affects surrounding normal skin.
References
- Pickering H, Mahon T. Azelaic acid in dermatology. Cutis. 1986. PubMed.
- Stein Gold LF, Jackson JM, Knuckles ML, Weiss JS. Topical dapsone in adult and adolescent women with acne vulgaris. J Drugs Dermatol. 2017. PubMed.
- Cestari TF, Dantas LP, Boza JC. Acquired hyperpigmentations: Tranexamic acid in the treatment of melasma. J Drugs Dermatol. 2014. PubMed.
Khabir Uddin is the founder of Elelaf Journal. This article is editorial, not medical advice. Prescription actives mentioned here require clinical evaluation; oral tranexamic acid in particular requires medical supervision because of contraindications.